vTv Therapeutics
VTVT
21 hedge funds and large institutions have $9.9M invested in vTv Therapeutics in 2025 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
31% more capital invested
Capital invested by funds: $7.57M → $9.9M (+$2.33M)
24% more funds holding
Funds holding: 17 → 21 (+4)
0.78% more ownership
Funds ownership: 21.13% → 21.9% (+0.78%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$261K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$157K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.58K |
| 5 |
CA
CoreCap Advisors
Southfield,
Michigan
|
+$752 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$58K |
| 2 |
JP Morgan Chase
New York
|
-$30.1K |
| 3 |
Morgan Stanley
New York
|
-$6.68K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$6.28K |
| 5 |
BlackRock
New York
|
-$1.15K |
VTVT Hedge Fund Activity: Q1 2025 in Review
21 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2025, worth a combined $9.9M — up 31% from $7.57M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VTVT positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $261K. The largest seller was UBS Group, cutting an estimated $58K.
- 21 institutional investors held vTv Therapeutics (VTVT) as of Q1 2025, up from 17 in Q4 2024.
- Funds reported $9.9M of vTv Therapeutics stock for Q1 2025, up 31% quarter-over-quarter.
- 5 funds opened new vTv Therapeutics positions in Q1 2025 and 1 closed out, a net change of +4 holders.
- The largest vTv Therapeutics buyer in Q1 2025 was Northern Trust, an estimated $261K added.
- The largest vTv Therapeutics seller in Q1 2025 was UBS Group, an estimated $58K sold.
Based on aggregated 13F filings for Q1 2025.